JLL, a Fortune 500 professional services firm, has designated the Research Triangle area, particularly Raleigh-Durham, as the premier biomanufacturing hub in the United States. In their 2023 overview report, JLL’s analysis focused on the life sciences sector, breaking down key components such as employment, job postings, degrees, venture capital funding, clinical trials, and industry concentration.
The decision to highlight biomanufacturing stemmed from the recognition that the life sciences sector encompasses more than just therapeutics research and development. It extends to impactful scientific endeavors like medical devices, technologies, and the increasingly influential field of biomanufacturing. The report showcases specific subsectors where certain markets exhibit strength.
Travis McCready, JLL’s head of life sciences, Americas markets, highlighted the value of narrowing the focus to biomanufacturing, providing clients with additional valuable information. The report commends North Carolina, specifically the Raleigh-Durham area, for its impressive biomanufacturing base, emphasizing the collaborative efforts of the state’s life sciences community.
The biomanufacturing sector rankings, detailed on page 26 of the report, position Raleigh-Durham at the top. Other notable hubs in the top five include the San Francisco Bay area, Greater Boston, Philadelphia, and New Jersey.
JLL attributes Raleigh-Durham’s success to its history of large-scale biomanufacturing in the Research Triangle Park and surrounding counties, supported by a critical mass of skilled workers. The region’s three tier-one universities contribute to a thriving research and development environment, fostering an emerging lab market. Additionally, Raleigh-Durham boasts a robust pipeline of pilot manufacturing real estate, ample land availability, a growing talent pool, and a business-friendly environment conducive to the entire drug development life cycle.
Bill Bullock, senior vice president of economic development and statewide operations at the North Carolina Biotechnology Center, expresses gratitude for JLL’s recognition. The acknowledgment is particularly meaningful as North Carolina celebrates the 40th anniversary of its Biotechnology Center, showcasing the state’s sustained growth in the biomanufacturing sector.
The report highlights North Carolina’s significant achievements in 2022, with $2.1 billion in new life sciences facilities and the promise of 2,700 new jobs statewide. Biomanufacturers continued this momentum in 2023, with announcements from industry leaders like Lilly, Invidior, and FUJIFILM Diosynth Biotechnologies. Projects include a $450 million expansion of Lilly’s pharmaceutical manufacturing facility, Invidior’s $60 million investment in a sterile manufacturing plant, and Janssen Supply Group becoming the first tenant in FUJIFILM Diosynth Biotechnologies’ $2 billion contract biomanufacturing site in Holly Springs, southwest of Raleigh.
Read the Full Article here-